For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they have in common is the loss of sufficient, intact nervous system circuits that orchestrate functions as varied as memory formation (in Alzheimer's) or voluntary motion (in movement disorders).
According to our (Global Info Research) latest study, the global CNS Therapeutics market size was valued at USD 78510 million in 2022 and is forecast to a readjusted size of USD 107370 million by 2029 with a CAGR of 4.6% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Mental health segment accounted for the largest market share in 2016. It is expected to retain its dominance over the forecast period owing to developing therapeutic options for mental diseases such as personality disorders and binge eating disorders. This segment is followed by degenerative disorders segment. There is growing awareness regarding neurodegenerative diseases owing to increase in initiatives by government and nongovernment organizations, such as Alzheimer's and Related Disorders Society of India. These organizations conduct awareness campaigns and conferences, such as Asia Pacific Conference of ADI at New Delhi and Kerala State Initiative on Dementia, which encourage the adoption of treatment for degenerative and mental disorders.
This report is a detailed and comprehensive analysis for global CNS Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global CNS Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global CNS Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global CNS Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global CNS Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for CNS Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global CNS Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Janssen Pharmaceuticals, Allergan, Lundbeck and Teva, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market segmentation
CNS Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Neurodegenerative Diseases
- Mood Disorders
- Schizophrenia
- Autism
- Depression
Market segment by Application
- Hospital Use
- Clinic Use
- Household
- Other
Market segment by players, this report covers
- Pfizer
- Janssen Pharmaceuticals
- Allergan
- Lundbeck
- Teva
- Camber Pharmaceuticals
- Zhejiang Haisen Pharmaceutical
- Jewim Pharmaceutical
- Cipla
- Merck Sharp & Dohme Corp.
- Eli Lilly
- GlaxoSmithKline
- Novartis
- LUPIN
- ZYDUS PHARMS
- Biogen
- Otsuka Pharmaceutical
- Astra Zeneca
- Takeda
Market segment by regions, regional analysis covers
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe CNS Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of CNS Therapeutics, with revenue, gross margin and global market share of CNS Therapeutics from 2018 to 2023.
Chapter 3, the CNS Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and CNS Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of CNS Therapeutics.
Chapter 13, to describe CNS Therapeutics research findings and conclusion.